Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

EFFECT OF DIABETES AND INSULIN ON THE MAXIMUM CAPACITY OF THE RENAL TUBULES TO REABSORB GLUCOSE
Saul J. Farber, … , Eugene Y. Berger, David P. Earle
Saul J. Farber, … , Eugene Y. Berger, David P. Earle
Published February 1, 1951
Citation Information: J Clin Invest. 1951;30(2):125-129. https://doi.org/10.1172/JCI102424.
View: Text | PDF
Research Article

EFFECT OF DIABETES AND INSULIN ON THE MAXIMUM CAPACITY OF THE RENAL TUBULES TO REABSORB GLUCOSE

  • Text
  • PDF
Abstract

Authors

Saul J. Farber, Eugene Y. Berger, David P. Earle

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 1988 1986 1985 1978 1977 1974 1973 1972 1971 1968 1965 1960 1959 1957 1955 1954 1953 Total
Citations: 1 2 1 7 12 9 6 15 10 14 15 17 5 5 4 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 144
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (144)

Title and authors Publication Year
Handling the sugar rush: the role of the renal proximal tubule
Spellman MJ 3rd, Assaf T, Nangia S, Fernandez J, Nicholson KC, Shepard BD
American Journal of Physiology - Renal Physiology 2024
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials.
Ji L, Mishra M, De Geest B
Pharmaceutics 2023
Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis.
Pozzi A, Cirelli C, Merlo A, Rea F, Scangiuzzi C, Tavano E, Iorio A, Kristensen SL, Wong C, Iacovoni A, Corrado G
Heart Failure Reviews 2023
The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
Oe Y, Vallon V
2022
Role of Insulin in Health and Disease: An Update
S Rahman, KS Hossain, S Das, S Kundu, EO Adegoke, A Rahman, A Hannan, J Uddin, MG Pang
International journal of molecular sciences 2021
Diabetes and Cardiovascular Risk in Renal Transplant Patients
J Rysz, B Franczyk, M Radek, A Ciałkowska-Rysz, A Gluba-Brzózka
International journal of molecular sciences 2021
Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences
GD GIUSEPPE, G CICCARELLI, CM CEFALO, F CINTI, S MOFFA, F IMPRONTA, U CAPECE, A PONTECORVI, A GIACCARI, T MEZZA
Minerva endocrinology 2021
Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge
M Provenzano, MC Pelle, I Zaffina, B Tassone, R Pujia, M Ricchio, R Serra, A Sciacqua, A Michael, M Andreucci, F Arturi
Frontiers in Medicine 2021
Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
N Srinivas, MK Sarnaik, S Modi, Y Pisipati, S Vaidya, NS Gaggatur, AH Sange, I Sange
Cureus 2021
Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease
S Ravindran, S Munusamy
Journal of Cellular Physiology 2021
Renal Tubular Handling of Glucose and Fructose in Health and Disease
Vallon V, Nakagawa T
Comprehensive Physiology 2021
The tubular hypothesis of nephron filtration and diabetic kidney disease
V Vallon, SC Thomson
Nature Reviews Nephrology 2020
Glucose transporters in the kidney in health and disease
V Vallon
Pflügers Archiv - European Journal of Physiology 2020
The use of sodium‐glucose co‐transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?
T Koufakis, OG Mustafa, RA Ajjan, X GarciaMoll, P Zebekakis, G Dimitriadis, K Kotsa
Journal of Clinical Pharmacy and Therapeutics 2020
Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport
E Ferrannini, R Pereira-Moreira, M Seghieri, E Rebelos, AL Souza, VB Chueire, C Arvia, E Muscelli
BMJ Open Diabetes Research & Care 2020
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
MR Cowie, M Fisher
Nature Reviews Cardiology 2020
Effect of Insulin on Proximal Tubules Handling of Glucose: A Systematic Review
R Pereira-Moreira, E Muscelli
Journal of Diabetes Research 2020
SGLT inhibitors as antidiabetic agents: a comprehensive review
Kshirsagar RP, Kulkarni AA, Chouthe RS, Pathan SK, Une HD, Reddy GB, Diwan PV, Ansari SA, Sangshetti JN
RSC Advances 2020
Insulin: Trigger and Target of Renal Functions
AF Pina, DO Borges, MJ Meneses, P Branco, R Birne, A Vilasi, MP Macedo
Frontiers in Cell and Developmental Biology 2020
Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development
E Gronda, M Jessup, M Iacoviello, A Palazzuoli, C Napoli
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 2020
Ominous Octet and Other Scary Diabetes Stories
SD Kelly, SL Neary
Physician Assistant Clinics 2020
Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
AP McGovern, M Hogg, BM Shields, NA Sattar, RR Holman, ER Pearson, AT Hattersley, AG Jones, JM Dennis
BMJ Open Diabetes Research & Care 2020
SGLT inhibitors as antidiabetic agents: a comprehensive review
RP Kshirsagar, AA Kulkarni, RS Chouthe, SK Pathan, HD Une, GB Reddy, PV Diwan, SA Ansari, JN Sangshetti
RSC Advances 2020
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
B Liu, Y Wang, Y Zhang, B Yan
Current topics in medicinal chemistry 2019
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors
E Brown, SP Rajeev, DJ Cuthbertson, JP Wilding
Diabetes, obesity & metabolism 2019
Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
E Brown, JP Wilding, TM Barber, U Alam, DJ Cuthbertson
Obesity reviews : an official journal of the International Association for the Study of Obesity 2019
Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors
E Cersosimo, JM Miles
Current diabetes reviews 2019
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
A Tentolouris, P Vlachakis, E Tzeravini, I Eleftheriadou, N Tentolouris
International journal of environmental research and public health 2019
Ion Channels and Transporters in Diabetic Kidney Disease
Spires D, Manis AD, Staruschenko A
Current topics in membranes 2019

Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice


YK Jiang, KY Xin, HW Ge, FJ Kong, G Zhao
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019
KIDNEY FUNCTION IN EXPERIMENTAL DIABETES
AY Zharikov, BA Balandovich, RO Shchekochikhina, GV Zharikova
2019
The Diabetes Textbook: Clinical Principles, Patient Management and Public Health Issues
J Rodriguez-Saldana
2019
Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
D Basu, LA Huggins, D Scerbo, J Obunike, AE Mullick, PL Rothenberg, NA Prospero, RH Eckel, IJ Goldberg
Arteriosclerosis, thrombosis, and vascular biology 2018
Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
E Bonora, R DeFronzo
2018
Effects of sodium glucose co-transporter 2 inhibitors on the kidney
N de Albuquerque Rocha, IJ Neeland, PA McCullough, RD Toto, DK McGuire
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2018
Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption
S Li, N Wang, X Guo, J Li, T Zhang, G Ren, D Li
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018
Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
E Bonora, RA DeFronzo
2018
Therapeutic medications against diabetes: What we have and what we expect
C Hu, W Jia
Advanced Drug Delivery Reviews 2018
Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential
ME Røder
Therapeutic Advances in Chronic Disease 2017
Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes
H Al-Jobori, G Daniele, E Cersosimo, C Triplitt, R Mehta, L Norton, RA DeFronzo, M Abdul-Ghani
Diabetes 2017
Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement
S Kalra, S Ghosh, AH Aamir, MT Ahmed, MF Amin, S Bajaj, MP Baruah, U Bulugahapitiya, AK Das, M Giri, S Gunatilake, SA Mahar, MF Pathan, NK Qureshi, SA Raza, R Sahay, S Shakya, D Shreshta, N Somasundaram, M Sumanatilleke, AG Unnikrishnan, AM Wijesinghe
Indian journal of endocrinology and metabolism 2017
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE
XX Wang, J Levi, Y Luo, K Myakala, M Herman-Edelstein, L Qiu, D Wang, Y Peng, A Grenz, S Lucia, E Dobrinskikh, VD D'Agati, H Koepsell, JB Kopp, AZ Rosenberg, M Levi
The Journal of biological chemistry 2017
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
E Ferrannini
Cell Metabolism 2017
The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes
K Jaikumkao, A Pongchaidecha, V Chatsudthipong, SC Chattipakorn, N Chattipakorn, A Lungkaphin
Biomedicine & Pharmacotherapy 2017
Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia
A Szalat, A Perlman, M Muszkat, M Khamaisi, Z Abassi, SN Heyman
Drug Safety 2017
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
D Kawanami, K Matoba, Y Takeda, Y Nagai, T Akamine, T Yokota, K Sango, K Utsunomiya
International journal of molecular sciences 2017
Empagliflozin: a new strategy for nephroprotection in diabetes
AI Korbut, VV Klimontov
Diabetes mellitus 2017
Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects: NORTON et al
L Norton, CE Shannon, M Fourcaudot, C Hu, N Wang, W Ren, J Song, M Abdul-Ghani, RA DeFronzo, J Ren, W Jia
Diabetes, obesity & metabolism 2017
Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes: SOLINI et al
A Solini, C Rossi, CM Mazzanti, A Proietti, H Koepsell, E Ferrannini
Diabetes, obesity & metabolism 2017
Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus
J Mondick, M Riggs, S Kaspers, N Soleymanlou, J Marquard, V Nock
Journal of clinical pharmacology 2017
The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
O Steen, RM Goldenberg
Canadian Journal of Diabetes 2017
SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?
N Ahmed-Sarwar, AK Nagel, S Leistman, K Heacock
The Annals of pharmacotherapy 2017
WITHDRAWN: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
O Steen, RM Goldenberg
Canadian Journal of Diabetes 2017
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
V Vallon, SC Thomson
Diabetologia 2016
Sodium–glucose cotransporter 2 inhibition: cardioprotection by treating diabetes—a translational viewpoint explaining its potential salutary effects
AE de Leeuw, RA de Boer
European Heart Journal - Cardiovascular Pharmacotherapy 2016
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
LA Gallo, MS Ward, AK Fotheringham, A Zhuang, DJ Borg, NB Flemming, BM Harvie, TL Kinneally, SM Yeh, DA McCarthy, H Koepsell, V Vallon, C Pollock, U Panchapakesan, JM Forbes
Scientific Reports 2016
Pharmacological analysis of SGLT2 inhibitor (tofogliflozin) using in vivo glucose clamp and titration protocols in rats and cynomolgus monkeys
M Fukazawa, T Nagata, M Suzuki, Y Suzuki, Y Kawabe
Folia Pharmacologica Japonica 2016
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
RA DeFronzo, L Norton, M Abdul-Ghani
Nature Reviews Nephrology 2016
The renal effects of SGLT2 inhibitors and a mini-review of the literature
V Andrianesis, S Glykofridi, J Doupis
Therapeutic Advances in Endocrinology and Metabolism 2016
The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
MR Weir
Postgraduate Medicine 2016
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
CI Choi
Molecules (Basel, Switzerland) 2016
Suppressing hyperinsulinemia prevents obesity but causes rapid onset of diabetes in leptin-deficient Lepob/ob mice
AM D'souza, JD Johnson, SM Clee, TJ Kieffer
Molecular Metabolism 2016
Abordaje de la diabetes mellitus tipo 2 a través del cotransportador sodio-glucosa tipo 2: ¿tiene sentido?
J Segura
Medicina Clínica 2016
Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
F Zaccardi, DR Webb, T Yates, MJ Davies
Postgraduate medical journal 2015
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
V Vallon
Annual Review of Medicine 2015
Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes
V Valentine, D Hinnen
Clinical diabetes : a publication of the American Diabetes Association 2015
Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
K Yamada, H Nakayama, S Yoshinobu, S Kawano, M Tsuruta, M Nohara, R Hasuo, S Akasu, I Tokubuchi, N Wada, S Hirao, S Iwata, H Kaku, Y Tajiri
Journal of Diabetes Investigation 2015
Renal Sodium-Glucose Cotransporter Inhibition in the Management of Type 2 Diabetes Mellitus
MA Abdul-Ghani, L Norton, RA DeFronzo
American journal of physiology. Renal physiology 2015
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
LA Gallo, EM Wright, V Vallon
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2015
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
P Fioretto, A Giaccari, G Sesti
Cardiovascular Diabetology 2015
International Textbook of Diabetes Mellitus: DeFronzo/International Textbook of Diabetes Mellitus, Fourth Edition
RN Bergman, M Ader
International Textbook of Diabetes Mellitus: DeFronzo/International Textbook of Diabetes Mellitus, Fourth Edition 2015
SGLT2 inhibitors
I Dardi, T Kouvatsos, SA Jabbour
Biochemical Pharmacology 2015
Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes
Y Nakamura, Y Nagai, Y Terashima, A Nishine, S Ishii, H Kato, A Ohta, Y Tanaka
Expert Opinion on Pharmacotherapy 2015
Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview
Juan F. Mosley II, Lillian Smith, Emily Everton, Chris Fellner
Pharmacy and Therapeutics 2015
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
J Rosenstock, E Ferrannini
Diabetes care 2015
The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes
PM Katz, LA Leiter
Canadian Journal of Diabetes 2015
Pharmacological and clinical profile of a novel SGLT2 inhibitor canagliflozin hydrate (CANAGLU®)
C Kuriyama, K Ueta, K Arakawa
Folia Pharmacologica Japonica 2015
Novel Agents for the Treatment of Type 2 Diabetes
RA DeFronzo, CL Triplitt, M Abdul-Ghani, E Cersosimo
Diabetes spectrum : a publication of the American Diabetes Association 2014
Impaired decline in renal threshold for glucose during pregnancy - a possible novel mechanism for gestational diabetes mellitus: High Renal Threshold for Glucose in GDM
P Klein, D Polidori, O Twito, A Jaffe
Diabetes/Metabolism Research and Reviews 2014
SGLT2 inhibitors in the treatment of type 2 diabetes
FM Hasan, M Alsahli, JE Gerich
Diabetes Research and Clinical Practice 2014
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
EM Lamos, LM Younk, SN Davis
Expert Opinion on Investigational Drugs 2014
Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes
S Sha, D Devineni, A Ghosh, D Polidori, M Hompesch, S Arnolds, L Morrow, H Spitzer, K Demarest, P Rothenberg, NC Barengo
PloS one 2014
Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
B Haas, N Eckstein, V Pfeifer, P Mayer, MD Hass
2014
Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes
JA Davidson, L Kuritzky
Postgraduate Medicine 2014
SGLT2 Inhibitors to Control Glycemia in Type 2 Diabetes Mellitus: A New Approach to an Old Problem
SA Jabbour
Postgraduate Medicine 2014
The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors
JP Wilding
Metabolism 2014
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control
EC Chao
Clinical diabetes : a publication of the American Diabetes Association 2014
Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease
G Vlotides, PR Mertens
Nephrology Dialysis Transplantation 2014
Sodium Glucose Cotransporter 2 Inhibitors
JR White
2014
SGLT-2 inhibition in patients with kidney disease
RE Gilbert
2014
Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport
MA Abdul-Ghani, RA DeFronzo
Journal of Internal Medicine 2014
Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin
T Kadokura, W Zhang, W Krauwinkel, S Leeflang, J Keirns, Y Taniuchi, I Nakajo, R Smulders
Clinical Pharmacokinetics 2014
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
JP Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel, G Meininger
International journal of clinical practice. Supplement 2013
Canagliflozin: a novel treatment option for type 2 diabetes
E Dietrich, J Powell, JR Taylor
Drug design, development and therapy 2013
Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
RR Poudel
Indian journal of endocrinology and metabolism 2013
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
E Ferrannini, SA Veltkamp, RA Smulders, T Kadokura
Diabetes care 2013
SGLT2 Inhibition: A Novel Prospective Strategy in Treatment of Diabetes Mellitus
AB Deshmukh, MC Patel, B Mishra
Renal Failure 2013
Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
E Kurosaki, H Ogasawara
Pharmacology & Therapeutics 2013
Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus: The Journal of Clinical Pharmacology
D Devineni, CR Curtin, D Polidori, MJ Gutierrez, J Murphy, S Rusch, PL Rothenberg
The Journal of Clinical Pharmacology 2013
Canagliflozin for the treatment of adults with Type 2 diabetes
PJ Aschner
Diabetes Management 2013
Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis: Role of SGLT2 in Tubular Apoptosis
S Maeda, T Matsui, M Takeuchi, S Yamagishi
Diabetes/Metabolism Research and Reviews 2013
SGLT2 inhibitors for diabetes: turning symptoms into therapy
M Diamant, LM Morsink
The Lancet 2013
Industrial natural product chemistry for drug discovery and development
A Bauer, M Brönstrup
Natural Product Reports 2013
Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans
Muhammad A Abdul-Ghani, Ralph A DeFronzo, Luke Norton
2013
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
Ralph A DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula, Xiaoni Liu, Ying Hong, Marc Pfister, Linda A Morrow, Bruce R Leslie, David W Boulton, Agatha Ching, Frank P LaCreta, Steven C Griffen
2013
Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized Trial
B Bode, K Stenlöf, D Sullivan, A Fung, K Usiskin
Hospital Practice 2013
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Ralph A. DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula, Xiaoni Liu, Ying Hong, Marc Pfister, Linda A. Morrow, Bruce R. Leslie, David W. Boulton, Agatha Ching, Frank P. LaCreta, Steven C. Griffen
2013
Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
Muhammad A. Abdul-Ghani, Ralph A. DeFronzo, Luke Norton
2013
Dapagliflozin for the treatment of type 2 diabetes
MA Abdul-Ghani, RA DeFronzo
Expert Opinion on Pharmacotherapy 2013
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
E Ferrannini, A Solini
Nature Reviews Endocrinology 2012
Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
MA Abdul-Ghani, L Norton, RA DeFronzo
Current Diabetes Reports 2012
Why Do SGLT2 Inhibitors Inhibit Only 30-50% of Renal Glucose Reabsorption in Humans?
J Liu, T Lee, RA DeFronzo
2012
Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
Y Liang, K Arakawa, K Ueta, Y Matsushita, C Kuriyama, T Martin, F Du, Y Liu, J Xu, B Conway, J Conway, D Polidori, K Ways, K Demarest, GP Fadini
PloS one 2012
Regulation of the human Na + -dependent glucose cotransporter hSGLT2
C Ghezzi, EM Wright
American journal of physiology. Cell physiology 2012
Antibodies in metabolic diseases
B Ahrens
New Biotechnology 2011
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
RA DeFronzo, JA Davidson, SD Prato
Diabetes Obesity and Metabolism 2011
Learning From Glycosuria
E Ferrannini
2011
A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition
J Basile
Postgraduate Medicine 2011
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
MA Abdul-Ghani, L Norton, RA DeFronzo
Endocrine reviews 2011
Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature
PA Carpino, B Goodwin
Expert Opinion on Therapeutic Patents 2010
SGLT2 inhibition — a novel strategy for diabetes treatment
EC Chao, RR Henry
Nature Reviews Drug Discovery 2010
Sodium-glucose transporter-2 inhibition as an antidiabetic therapy
E Ferrannini
Nephrology Dialysis Transplantation 2010
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
E Ferrannini, SJ Ramos, A Salsali, W Tang, JF List
2010
Glucose Control by the Kidney: An Emerging Target in Diabetes
O Marsenic
American Journal of Kidney Diseases 2009
Novartis Foundation Symposia
EJ Campbell
Ciba Foundation Symposium 44 - Research and Medical Practice: Their Interaction 2008
Diabetes Mellitus
MA Sperling, SA Weinzimer, WV Tamborlane
Pediatric Endocrinology 2008
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
JF List, V Woo, E Morales, W Tang, FT Fiedorek
2008
Biological Monitoring of Toxic Metals
TW Clarkson, L Friberg, GF Nordberg, PR Sager
1988
Enhancement of glomerular filtration rate and renal plasma flow by oral glucose load in well controlled insulin-dependent diabetics
JS Christiansen, CK Christensen, K Hermansen, EB Pedersen, CE Mogensen
Scandinavian Journal of Clinical & Laboratory Investigation 1986
Kinetic studies of d-glucose transport in renal brush-border membrane vesicles of streptozotocin-induced diabetic rats
ME Blank, F Bode, E Huland, DF Diedrich, K Baumann
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1985
Klinik der inneren Sekretion
A Labhart
1978
Diabetes mellitus • B
R Beckmann, M Berger, A Beringer, P Berchtold, J Beyer, A Bischoff, G Brehm, BF Clarke, GR Constam, LJ Duncan, FA Gries, A Hasselblatt, R Hild, K Irmscher, K Jahnke, J Kühnau, H Liebermeister, K Lundbaek, G Meyer-Schwickerath, S Napp-Mellinghoff, M Neubauer, F Nobbe, K Oberdisse, P Petrides, R Petzoldt, H Sauer, K Schöffling, M Spitznas, J Steinke, M Vogel, KH Vogelberg, A Wessing
1977
La glicosuria
S Marigo
Acta Diabetologica Latina 1974
THE GLOMERULAR FILTRATION RATE DURING MODERATE HYPERGLYCEMIA IN NORMAL MAN
J Brøchner-Mortensen
Acta Medica Scandinavica 1973
Zur Wirkung von Glucose und Insulin auf die renale Kaliumausscheidung der gesunden und insuffizienten Niere
H Ludwig, L Heuer
Research in Experimental Medicine 1972
Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic Subjects
CE Mogensen
Scandinavian Journal of Clinical & Laboratory Investigation 1971
Nierenkrankheiten
H Schwiegk, E Buchborn, K Čapek, P Deetjen, J Eigler, K Federlin, R Heintz, J Heller, H Jesserer, A Kleinschmidt, F Krück, J Martínek, EF Pfeiffer, R Richterich, G Riecker, K Thurau, F Wahlig, H Wirz, HU Zollinger
1968
Physiologie und Pathologische Physiologie / Physiology and Pathological Physiology / Physiologie Normale et Pathologique
B Fey, F Heni, A Kuntz, DF McDonald, L Quénu, LG Wesson, C Wilson
1965
Ergebnisse der Inneren Medizin und Kinderheilkunde
L Heilmeyer, R Schoen, B Rudder
1960
Managing Unmanageable Edema
EY Berger
Postgraduate Medicine 1959
Physiologic aspects of glomerulonephritis
SJ Farber
Journal of Chronic Diseases 1957
Renal glycosuria
L Horowitz, S Schwarzer
The Journal of Pediatrics 1955
The effect of insulin on the excretion of glucose and phosphate by the kidney of the cat
MG Eggleton, S Shuster
The Journal of Physiology 1954
Die Stellung der Niere im Kohlenhydratstoffwechsel
A Kleinschmidt
Klinische Wochenschrift 1953

← Previous 1 2 3 4 5 6 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts